This trial is evaluating whether Genetically Engineered NY-ESO-1-specific T Lymphocytes will improve 1 primary outcome and 6 secondary outcomes in patients with Relapse. Measurement will happen over the course of Up to 28 days post infusion.
This trial requires 9 total participants across 1 different treatment group
This trial involves a single treatment. Genetically Engineered NY-ESO-1-specific T Lymphocytes is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"The following signs are related to early carcinoma: elevated body temperature, an irregular bowel movement, weight loss and/or dehydration, and a lump in the breast. The signs are present only a few days or weeks before diagnosis, and do not always occur with tumor." - Anonymous Online Contributor
"Incidence of cancer continues to rise in this population. Current population estimate of cancer incidence is 20-fold higher than the estimate from the 1970 U.S. census. Future trends are likely to be greater, given the demographic shifts in the US." - Anonymous Online Contributor
"Tumor type or grade is an important consideration in treatment, and cancer treatment is broadly categorized into two categories: curative or palliative. More aggressive tumor or metastatic disease is often treated with chemotherapy, surgery, or radiotherapy. More localized disease is treated with surgery, chemotherapy, or radiation therapy. Non-curative therapy options, especially if systemic metastases are present, are often used in combination with multiple treatments in an effort to prolong survival. Chemotherapy typically includes anthracyclines, taxanes, and epoetins. Targeted therapy agents, including agents targeting the epidermal growth factor receptor or the vascular endothelial growth factor pathway, are used to treat lung cancer with metastases." - Anonymous Online Contributor
"For most patients, curative treatments include: surgery, such as a curative excision, radical mastectomy, or mastectomy with (chemo)-radiation or chemo-radiation alone; radiotherapy and radiochemotherapy. For all but two of our patients we also used the following: chemotherapy or chemotherapy-radiotherapy with corticoid-cimetidine, which in several patients brought some good results." - Anonymous Online Contributor
"The majority of cancers are non-hereditary, probably related to a combination of genetic and environmental factors, especially tobacco smoking and exposure to carcinogens in many workplaces, as well as diet and other lifestyles that are related to the development of certain types of cancer." - Anonymous Online Contributor
"While cancer, of course, can be the first or second indication for surgery, it can also be metastatic or the recurrence of an earlier surgical procedure. For a few cancers, there are effective treatment options. In most types of cancer, you cannot avoid the risks associated with treatment (particularly complications following surgery) if the patient intends to undergo surgery. Use the [Power(http://www.withpower.com/clinical-trials/tumor-treatments-clinical-trials)\n\n- powerlawit\n- powerlawit.org\n- powerlawit." - Anonymous Online Contributor
"TCRs of the ny-eso-1-specific repertoire recognise only a part of the peptide epitope of pny-1. These data should help in further elucidating the mechanism, and possibly improving generation of MHC class II-restricted ny-eso-1-reactive TCRs against an epitope restricted antigen and for the treatment of CML." - Anonymous Online Contributor
"Data from a recent study indicate that ny-eso-1-specific CTLs exert the antitumor effect and decrease tumor-associated cytokines in patients with esophageal carcinoma. Moreover, the clinical effect appears long-lasting. Data from a recent study suggest that adoptive transfer of cancer-specific cytotoxic T-cells may have the potential for clinical use in a large proportion of patients with esophageal cancer." - Anonymous Online Contributor
"The survival rate for carcinoma was 34.4% for patients who were diagnosed during 1978–79 and 38.4% for those diagnosed during 1981–85 at the Mayo Clinic. Survival was not significantly higher for patients diagnosed at all centers. A better understanding of the relationship between survival and treatment is needed." - Anonymous Online Contributor
"Findings from a recent study on the effectiveness of a tn-eso-1 vaccine suggest that in the study in rhesus monkeys the most likely side effects were related to the development of GVHD and the production of autoantibodies. An efficient preparation (vaccine-induced esophageal toxicity-free) was created with a low side risk. In contrast to our in vitro data on IL-17, it turned out that the most popular cytokine was TNF-α." - Anonymous Online Contributor
"Carcinoma is a fatal disease that affects approximately 300,000 people in the United States each year. In the [early stages] it may be curable with cancer surgery. However, in the [later stages] it can spread to distant sites. This leads to the patient suffering through prolonged morbidity and high mortality. When an individual is diagnosed with carcinoma, the possibility that they may be cured can be very high. However, those with cancer have very few good treatments. These patients experience side effects from chemotherapy in addition to surgery, radiation, and other treatment options. To [find out who is most likely to benefit from cancer treatment,] ask their physicians for a [prognostic score](power." - Anonymous Online Contributor
"There are no clear indications for performing a clinical trial in patients with advanced carcinoma. Some indications exist and most of these are already used in clinical practice. The type of information that would be useful in the indication for a clinical trial is difficult to define. We discuss the potential uses of a clinical trial on the basis of current knowledge and clinical guidelines." - Anonymous Online Contributor